Xoma Corp (XOMA-Q) Stock Price and News - The Globe and Mail

Add to Watchlist Create Alerts

Real-Time Last Update

Last Sale Cboe BZX Real-Time

Volume

Day Low25.51

Day High26.14

Open:26.14

Previous Close

52-Week High/Low

Volume

Average Volume

Price/Earnings (TTM)

Forward Annual Dividend & Yield

Market Capitalization, $M

5-Day Change

Realtime quote and/or trade prices are not sourced from all markets.

XOMA Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Events

XOMA Declares Quarterly Preferred Stock Dividends

XOMA to Present at H.C. Wainwright Global Investment Conference

XOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational Events

XOMA Declares Quarterly Preferred Stock Dividends

XOMA to Present at Oppenheimer’s 32nd Annual Healthcare Conference

XOMA Reports Full Year 2021 Financial Results and Highlights Recent Operational Events

XOMA to Present at the 42nd Annual Cowen Health Care Conference

XOMA to Present at Aegis Capital Corp Investor Conference

February 17, 2022

XOMA Declares Quarterly Preferred Stock Dividends

December 23, 2021

XOMA to Present at Upcoming Investor Conferences

December 21, 2021

XOMA Announces Evolution of Company Leadership and Succession Planning

December 16, 2021

XOMA Earns $35 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Clinical Study in Metastatic Pancreatic Cancer

November 4, 2021

XOMA Reports Third Quarter 2021 Financial Results and Highlights Recent Operational Events

November 4, 2021

XOMA to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

September 22, 2021

XOMA Declares Quarterly Preferred Stock Dividends

September 20, 2021

XOMA to Present at H.C. Wainwright 23rd Annual Global Investment Conference

September 13, 2021

XOMA Announces Heather L. Franklin Joins its Board of Directors

August 10, 2021

XOMA Reports Second Quarter 2021 Financial Results and Highlights Recent Operational Events

U.S. Food and Drug Administration has Granted Orphan Drug Designation to XOMA’s Licensed anti-TGFβ Asset NIS793

Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros’s license agreement with Checkmate Pharmaceuticals

XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Biosciences

XOMA Declares Quarterly Preferred Stock Dividends

XOMA Licensees to Present Significant Clinical Data at 2021 ASCO Annual Meeting

XOMA Reports First Quarter 2021 Financial Results and Highlights Recent Operational Events

XOMA Earns Milestone for First Patient Dosed in Phase 3 Development Program

XOMA’s Royalty Portfolio Grows with Addition of Three Royalty Assets

XOMA Announces Closing of Depositary Shares Offering and Exercise of Underwriters’ Option

XOMA Prices $35 Million Offering of Depositary Shares

XOMA Announces Offering of Depositary Shares and Series B Cumulative Perpetual Preferred Stock

XOMA Announces Approval of First Preferred Stock Dividend

XOMA Reports Fourth Quarter and Full-Year 2020 Financial Results and Operating Highlights

Profile

XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1' with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California.